Literature DB >> 12628936

Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.

Jodi R Alt1, Timothy C Greiner, John L Cleveland, Christine M Eischen.   

Abstract

Mdm2 harnesses the p53 tumor suppressor, yet loss of one Mdm2 allele in Mdm2(+/-) mice has heretofore not been shown to impair tumor development. Here we report that Mdm2 haplo-insufficiency profoundly suppresses lymphomagenesis in E micro -myc transgenic mice. Mdm2(+/-)E micro -myc transgenics had greatly protracted rates of B cell lymphoma development with life spans twice that of wild-type transgenic littermates. Im paired lymphoma development was associated with drastic reductions in peripheral B cell numbers in Mdm2(+/-)E micro -myc transgenics, and primary pre-B cells from Mdm2(+/-)E micro -myc transgenics and Mdm2(+/-) littermates were extremely susceptible to spontaneous apoptosis. Loss of p53 rescued all of the effects of Mdm2 haplo-insufficiency, indicating they were p53 dependent. Furthermore, half of the lymphomas that ultimately emerged in Mdm2(+/-)E micro -myc transgenics harbored inactivating mutations in p53, and the majority overcame haplo-insufficiency by overexpressing Mdm2. These results support the concept that Mdm2 functions are rate limiting in lymphomagenesis and that targeting Mdm2 will enhance p53-mediated apoptosis, compromising tumor development and/or maintenance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628936      PMCID: PMC151074          DOI: 10.1093/emboj/cdg133

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

Review 1.  Cellular senescence: mitotic clock or culture shock?

Authors:  C J Sherr; R A DePinho
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

2.  Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.

Authors:  C M Eischen; D Woo; M F Roussel; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  p53-independent functions of the p19(ARF) tumor suppressor.

Authors:  J D Weber; J R Jeffers; J E Rehg; D H Randle; G Lozano; M F Roussel; C J Sherr; G P Zambetti
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

4.  A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2.

Authors:  M T Boyd; N Vlatkovic; D S Haines
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

5.  Nucleolar Arf sequesters Mdm2 and activates p53.

Authors:  J D Weber; L J Taylor; M F Roussel; C J Sherr; D Bar-Sagi
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

6.  p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.

Authors:  K B Pagnano; J Vassallo; I Lorand-Metze; F F Costa; S T Saad
Journal:  Am J Hematol       Date:  2001-06       Impact factor: 10.047

7.  A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.

Authors:  L Li; J Liao; J Ruland; T W Mak; S N Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

8.  The loss of mdm2 induces p53-mediated apoptosis.

Authors:  S de Rozieres; R Maya; M Oren; G Lozano
Journal:  Oncogene       Date:  2000-03-23       Impact factor: 9.867

9.  Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.

Authors:  C M Eischen; M F Roussel; S J Korsmeyer; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

10.  Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.

Authors:  D A Freedman; A J Levine
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  59 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.

Authors:  Susan M Mendrysa; Keiko Akagi; Jean Roayaei; Wen-Hui Lien; Neal G Copeland; Nancy A Jenkins; Robert N Eisenman
Journal:  Genes Cancer       Date:  2010-05

3.  Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.

Authors:  Jayne M Stommel; Geoffrey M Wahl
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

4.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

5.  Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Authors:  M W Gramling; C M Eischen
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

6.  Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.

Authors:  Ai Kotani; Naoki Kakazu; Tatsuaki Tsuruyama; Il-mi Okazaki; Masamichi Muramatsu; Kazuo Kinoshita; Hitoshi Nagaoka; Daisuke Yabe; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-24       Impact factor: 11.205

Review 7.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 8.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 9.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

10.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.